Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$6 Mln
P/E Ratio
--
P/B Ratio
4.84
Industry P/E
--
Debt to Equity
-0.18
ROE
-8.63 %
ROCE
621.18 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-47.58 Mln
EBITDA
$-55.46 Mln
Net Profit
$-60.73 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
NLS Pharmaceutics (NLSP)
| -28.91 | -0.66 | -15.73 | -70.00 | -66.75 | -- | -- |
|
BSE Sensex*
| 2.33 | 3.18 | 6.24 | 8.60 | 12.11 | 20.33 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
|
|---|---|---|
|
NLS Pharmaceutics (NLSP)
| -54.27 | 16.22 |
|
S&P Small-Cap 600
| 13.89 | -17.42 |
|
BSE Sensex
| 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 1.33 | 131.91 | -- | 89.97 | |
| 0.06 | 2.89 | -- | 531.41 | |
| 38.27 | 3,377.66 | -- | -19.2 |
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for... narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with NeuroLife-Sciences SAS for use of mazindol for the treatment of ADHD; and Eurofarma Laboratorios S.A. for commercialization and distribution of Nolazol in Latin America. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland. Read more
President, CEO & Director
Mr. Alexander Zwyer M.B.A.
President, CEO & Director
Mr. Alexander Zwyer M.B.A.
Headquarters
Zurich
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of NLS Pharmaceutics Ltd (NLSP) stood at $ 2 Mln as on 31-Dec-23
The share price of NLS Pharmaceutics Ltd (NLSP) is $1.50 (NASDAQ) as of 25-Apr-2025 16:00 EDT. NLS Pharmaceutics Ltd (NLSP) has given a return of -66.75% in the last 3 years.
NLS Pharmaceutics Ltd (NLSP) has a market capitalisation of $ 6 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of NLS Pharmaceutics Ltd (NLSP) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the NLS Pharmaceutics Ltd (NLSP) and enter the required number of quantities and click on buy to purchase the shares of NLS Pharmaceutics Ltd (NLSP).
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with NeuroLife-Sciences SAS for use of mazindol for the treatment of ADHD; and Eurofarma Laboratorios S.A. for commercialization and distribution of Nolazol in Latin America. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.
The CEO & director of Mr. Alexander Zwyer M.B.A.. is NLS Pharmaceutics Ltd (NLSP), and CFO & Sr. VP is Mr. Alexander Zwyer M.B.A..
There is no promoter pledging in NLS Pharmaceutics Ltd (NLSP).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
408
|
|
|
21
|
|
|
1
|
|
|
408
|
| NLS Pharmaceutics Ltd. (NLSP) | Ratios |
|---|---|
|
Return on equity(%)
|
438.42
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of NLS Pharmaceutics Ltd (NLSP) was No Profit.
